RU2017124141A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017124141A3 RU2017124141A3 RU2017124141A RU2017124141A RU2017124141A3 RU 2017124141 A3 RU2017124141 A3 RU 2017124141A3 RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A RU2017124141 A RU 2017124141A RU 2017124141 A3 RU2017124141 A3 RU 2017124141A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089097P | 2014-12-08 | 2014-12-08 | |
| US62/089,097 | 2014-12-08 | ||
| US201562200557P | 2015-08-03 | 2015-08-03 | |
| US62/200,557 | 2015-08-03 | ||
| PCT/US2015/064572 WO2016094456A1 (en) | 2014-12-08 | 2015-12-08 | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017124141A RU2017124141A (ru) | 2019-01-10 |
| RU2017124141A3 true RU2017124141A3 (OSRAM) | 2019-06-19 |
| RU2725807C2 RU2725807C2 (ru) | 2020-07-06 |
Family
ID=56108081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017124141A RU2725807C2 (ru) | 2014-12-08 | 2015-12-08 | Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12247062B2 (OSRAM) |
| EP (1) | EP3230311B1 (OSRAM) |
| JP (2) | JP7095992B2 (OSRAM) |
| KR (1) | KR102654033B1 (OSRAM) |
| CN (1) | CN107108718B (OSRAM) |
| AU (1) | AU2015360642B2 (OSRAM) |
| CA (1) | CA2968987C (OSRAM) |
| NZ (1) | NZ732073A (OSRAM) |
| RU (1) | RU2725807C2 (OSRAM) |
| SG (1) | SG11201704124YA (OSRAM) |
| WO (1) | WO2016094456A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CA2968987C (en) | 2014-12-08 | 2022-05-10 | 1Globe Biomedical Co., Ltd. | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| AU2021301788A1 (en) * | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| NZ241855A (en) * | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| ATE218143T1 (de) * | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| HK1041221A1 (zh) * | 1998-08-11 | 2002-07-05 | Idec药物公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
| WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| KR101130181B1 (ko) * | 2003-02-27 | 2012-03-28 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물 |
| CN1822857A (zh) | 2003-06-02 | 2006-08-23 | 阿莱克申药物公司 | 去免疫原性抗cd3抗体 |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| DK1716178T3 (da) * | 2004-02-16 | 2010-09-20 | Micromet Ag | Mindre immunogene bindingsmolekyler |
| US20080003225A1 (en) | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| EP2124994A2 (en) * | 2007-01-23 | 2009-12-02 | Zymogenetics, Inc. | Soluble fc gamma r1a for reducing inflammation |
| US8043621B2 (en) * | 2007-05-10 | 2011-10-25 | Ramot At Tel Aviv University Ltd. | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| AU2011349049B2 (en) | 2010-12-22 | 2016-08-11 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| CA2858389A1 (en) * | 2011-12-15 | 2013-06-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Soluble igf receptor fc fusion proteins and uses thereof |
| US20150037334A1 (en) * | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| CA2968987C (en) | 2014-12-08 | 2022-05-10 | 1Globe Biomedical Co., Ltd. | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
-
2015
- 2015-12-08 CA CA2968987A patent/CA2968987C/en active Active
- 2015-12-08 NZ NZ732073A patent/NZ732073A/en not_active IP Right Cessation
- 2015-12-08 RU RU2017124141A patent/RU2725807C2/ru active
- 2015-12-08 AU AU2015360642A patent/AU2015360642B2/en not_active Ceased
- 2015-12-08 US US15/532,770 patent/US12247062B2/en active Active
- 2015-12-08 KR KR1020177018958A patent/KR102654033B1/ko active Active
- 2015-12-08 WO PCT/US2015/064572 patent/WO2016094456A1/en not_active Ceased
- 2015-12-08 SG SG11201704124YA patent/SG11201704124YA/en unknown
- 2015-12-08 CN CN201580064820.XA patent/CN107108718B/zh active Active
- 2015-12-08 EP EP15867381.4A patent/EP3230311B1/en active Active
- 2015-12-08 JP JP2017530141A patent/JP7095992B2/ja active Active
-
2020
- 2020-11-30 JP JP2020198225A patent/JP2021035994A/ja active Pending
-
2022
- 2022-04-12 US US17/719,194 patent/US20220235115A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3230311B1 (en) | 2022-01-26 |
| SG11201704124YA (en) | 2017-06-29 |
| WO2016094456A1 (en) | 2016-06-16 |
| JP2021035994A (ja) | 2021-03-04 |
| KR20170089003A (ko) | 2017-08-02 |
| JP7095992B2 (ja) | 2022-07-05 |
| CN107108718A (zh) | 2017-08-29 |
| KR102654033B1 (ko) | 2024-04-02 |
| RU2017124141A (ru) | 2019-01-10 |
| AU2015360642A1 (en) | 2017-06-08 |
| AU2015360642B2 (en) | 2019-04-04 |
| JP2018502068A (ja) | 2018-01-25 |
| CA2968987C (en) | 2022-05-10 |
| EP3230311A4 (en) | 2018-05-30 |
| CN107108718B (zh) | 2022-07-22 |
| EP3230311A1 (en) | 2017-10-18 |
| CA2968987A1 (en) | 2016-06-16 |
| US20220235115A1 (en) | 2022-07-28 |
| RU2725807C2 (ru) | 2020-07-06 |
| NZ732073A (en) | 2019-04-26 |
| US12247062B2 (en) | 2025-03-11 |
| US20170362299A1 (en) | 2017-12-21 |